BXMT Q2 2025 Earnings Call Transcript

Agios reported Q2 net revenue of $12.5 million, up 45% year over year and 44% sequentially, while ending the quarter with $1.3 billion in cash and securities. Management reiterated 2025 revenue guidance for modest growth, highlighted a September 7 PDUFA date for PYRUKYND in thalassemia, and said launch preparations are largely in place with SG&A expected to step up further after approval. Pipeline progress also remained active, including first patient dosed in tebapivat Phase II sickle cell disease and IND clearance for AG-236 in polycythemia vera.

Analysis

The real read-through is that this is no longer a single-product story but a staged commercialization reset. The near-term trade is not on this quarter's revenue print; it's on whether management can convert a very concentrated rare-disease prescriber base into a durable launch engine before the U.S. label decision. If approved, the first revenue step-up is likely to be slower than bulls expect because initiation lags, payer friction, and cautious physician behavior around liver-risk language will cap early uptake even with a pre-built sales force.

The more interesting second-order effect is competitive: a successful thalassemia launch would pressure legacy supportive-care economics first, then pull share from the gray zone of symptomatic but non-transfusion-dependent patients who are under-treated today. That segment is where the company can surprise to the upside, because it is less about switching entrenched transfusion-dependent patients and more about creating treatment in a population that is already visible in claims data but not actively managed. Ex-U.S. partnerships reduce capital burn but also defer the economic upside, so the equity should trade primarily off U.S. launch execution and the label rather than headline global TAM.

From a risk standpoint, the market is still underestimating how much the hepatocellular injury discussion can compress first-year penetration if the final warning language is stricter than expected. The more severe the label, the more the launch becomes an education-and-monitoring exercise rather than a volume event, which would push meaningful revenue out by several quarters. That said, the balance sheet gives them optionality: the downside case is not solvency, it's multiple compression if the FDA outcome is merely adequate instead of clearly clean. The bigger upside catalyst beyond the PDUFA is the sickle cell readout later this year; if that is positive, the stock can re-rate from a one-asset launch story into a multi-asset franchise story.

Key Decisions for Investors

• Long AGIO into the PDUFA window, but size as a catalyst trade rather than a core position: best risk/reward is 2-6 weeks pre-decision, with the thesis that approval + manageable label drives a sharp multiple reset.
• Buy AGIO Jan-2026 or Mar-2026 calls / call spread to express upside from a positive label and later sickle cell readout; prefer defined-risk structures because label uncertainty can gap the stock both ways.
• If already long, hedge event risk by selling out-of-the-money calls into the decision or by pairing long AGIO against short a supportive-care-heavy rare-disease peer basket to isolate launch execution alpha.
• Post-approval, add on any initial selloff if the market overreacts to slow 4Q revenue recognition; the first-year revenue ramp should be judged on prescription conversion, not Q3/Q4 revenue alone.
• Avoid chasing ex-U.S. partnership enthusiasm in the near term; those economics are long-dated and should be treated as balance-sheet validation, not an immediate EPS driver.